Prophylaktische zytolytische Behandlung nach Herztransplantation: ATG versus OKT3. [Preventive cytolytic treatment following heart transplantation: ATG versus OKT3]

Details

Serval ID
serval:BIB_27C848CC8FDA
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prophylaktische zytolytische Behandlung nach Herztransplantation: ATG versus OKT3. [Preventive cytolytic treatment following heart transplantation: ATG versus OKT3]
Journal
Helvetica Chirurgica Acta
Author(s)
Laske  A., Leonardi  L., Gallino  A., Bauer  E., Carrel  T., Schonbeck  M., von Segesser  L. K., Turina  M.
ISSN
0018-0181
Publication state
Published
Issued date
01/1991
Volume
57
Number
4
Pages
611-7
Notes
English Abstract
Journal Article --- Old month value: Jan
Abstract
The postoperative prophylactic cytolytic therapy with rabbit-ATG and OKT3 after heart transplantation are compared. The first 20 recipients were treated with ATG (5 days), the next 20 with OKT3 (14 days). The medium histological rejection grade (Texas classification) was significantly higher after 2 weeks in ATG group and after 4 weeks in OKT3 group. The linearised rejection rate was 7.1 (ATG) vs. 0.7 (OKT3) (p less than 0.005) at 2 weeks, resp. 3.6 vs. 8.6 (p less than 0.05) and 1.3 vs. 2.9 (p less than 0.005) at 4 weeks and 2 months. After 3 months there was no difference in histological rejection grade (3.6 +/- 1.5 vs. 3.3 +/- 1.7) and linearised rejection rate (2.4 vs. 2.6 per 100 days and patient) between the two groups. Severe rejections are more frequent after OKT3 (6 vs. 11) and probability of rejection free survival is higher after ATG (25% vs. 0%, resp. 21% vs. 0% after 2 resp. 3 months; p less than 0.05). In this study we find no short and medium term benefit of a rejection prophylaxis with OKT3 (14 days) compared with ATG (5 days). Acute allograft rejections in OKT3 group tend to be more severe with a higher mortality.
Keywords
Antibodies, Monoclonal/*administration & dosage/immunology Antigens, CD3 Antigens, Differentiation, T-Lymphocyte/*immunology Antilymphocyte Serum/*administration & dosage Chronic Disease Follow-Up Studies Graft Rejection/*drug effects/immunology Heart Transplantation/*immunology Humans Postoperative Complications/mortality Receptors, Antigen, T-Cell/*immunology Survival Rate T-Lymphocytes/*immunology
Pubmed
Web of science
Create date
14/02/2008 15:18
Last modification date
20/08/2019 14:07
Usage data